A-dmDT390-bisFv(UCHT1)

A-dmDT390-bisFv(UCHT1), also known as Resimmune, is an investigational bivalent recombinant fusion protein immunotoxin designed for the treatment of T cell malignancies such as cutaneous T-cell lymphoma and other CD3+ T cell cancers. It consists of the first 390 amino acids of diphtheria toxin (DT) fused to two tandem single-chain variable fragments (sFv) derived from the UCHT1 monoclonal antibody, which targets human CD3 epsilon on T cells. The DT moiety inhibits protein synthesis by ADP ribosylation of elongation factor 2, leading to selective cytotoxicity against malignant and normal CD3+ T cells, with malignant cells being significantly more sensitive. The drug is under development by Angimmune and originated at the National Institutes of Health. Its primary indications are cutaneous T-cell lymphoma and malignant melanoma[1][2][3][4][5].

Brand names

resimmune

Other names

anti-cd3 immunotoxin a-dmdt390-bisfv(ucht1)recombinant anti-cdr-bi-single-chain-fv-diphtheria toxin fusion proteinrecombinant anti-cdr-bi-single-chain-fv-diptheria toxin fusion proteina-dmdt390-bisfva-dmdt-390-bisfva-dmdt 390-bisfvanti-cd3 antibody-diphtheria toxin conjugateanti-cd-3 antibody-diphtheria toxin conjugateanti-cd 3 antibody-diphtheria toxin conjugateanti-cd3 bivalent antibody-diphtheria toxin conjugateanti-cd-3 bivalent antibody-diphtheria toxin conjugateanti-cd 3 bivalent antibody-diphtheria toxin conjugate